However, different studies have also shown that suppressing NOE contrast, often decreased in glioma compared to healthy‐appearing brain tissue, allowed more reliable characterization of the enhancing lesions of glioblastomas and differentiation between glioma grades, considering the IDH mutations and MGMT methylation status.35 The gene discussed is IDH2; the disease is central nervous system cancer.